Ibogaine Before
& After

About These Patient Stories

All patient journeys presented on this page are based on real outcomes from MindScape Retreat, with names and identifying details changed to protect privacy. Clinical scores (CAPS-5, PHQ-9, AUDIT, GAD-7) are from validated instruments administered by our clinical team.

Individual results vary significantly based on substance history, duration of use, co-occurring conditions, adherence to preparation protocols, and engagement with aftercare. Ibogaine treatment carries medical risks including cardiac complications and should only be administered in a medically supervised clinical setting with proper screening.

These outcomes represent our clinical observations and are not intended as guarantees. We encourage all prospective patients to review our safety protocols and schedule a confidential medical evaluation to determine eligibility.

Before Treatment

• ×8 years of opioid dependency, last 3 on illicit fentanyl
• ×5 failed rehab programs (30-day, 90-day, MAT)
• ×Daily fentanyl use: 15-20 pressed pills
• ×Severe withdrawal every 6-8 hours
• ×Lost career, marriage, and custody of 2 children
• ×3 non-fatal overdoses in final year

After Treatment

• ✓Zero opioid cravings by hour 36 post-treatment
• ✓No withdrawal symptoms from day 2 onward
• ✓Returned to work within 6 weeks
• ✓Regained partial custody at 4 months
• ✓18 months clean at last follow-up
• ✓Completed 90-day integration program

Before Treatment

• ×PTSD from childhood trauma, diagnosed at 24
• ×12 years on SSRIs and benzodiazepines
• ×CAPS-5 score: 62 (severe PTSD)
• ×PHQ-9 score: 22 (severe depression)
• ×3 psychiatric hospitalizations
• ×Unable to maintain employment for >6 months

After Treatment

• ✓CAPS-5 score dropped to 8 (sub-clinical) at 30 days
• ✓PHQ-9 score: 4 (minimal depression) at 30 days
• ✓Successfully tapered all psychiatric medications
• ✓Returned to full-time work within 3 months
• ✓No depressive episodes at 12-month follow-up
• ✓Reports sustained emotional regulation

Before Treatment

• ×Transitioned from heroin to methadone clinic at age 31
• ×Stable on 120mg methadone daily for 6 years
• ×Multiple failed taper attempts (severe withdrawal at 40mg)
• ×Emotional blunting, weight gain (+45 lbs), chronic fatigue
• ×Daily clinic visits impacting employment
• ×Testosterone levels severely depleted

After Treatment

• ✓Completed pre-treatment methadone taper (120mg → 30mg over 8 weeks)
• ✓Zero methadone by day 3 post-ibogaine
• ✓Lost 30 lbs in first 4 months (natural appetite regulation)
• ✓Testosterone normalized within 3 months
• ✓Emotional range restored — reports crying for first time in years
• ✓14 months methadone-free at last follow-up

Before Treatment

• ×Daily alcohol consumption: 1-2 bottles of wine
• ×AUDIT score: 28 (severe alcohol use disorder)
• ×GAD-7 score: 18 (severe anxiety)
• ×Liver enzymes elevated (ALT 78, AST 65)
• ×2 medically supervised detox programs
• ×Social isolation, panic attacks 3-4x weekly

After Treatment

• ✓Zero alcohol cravings from day 5 post-treatment
• ✓AUDIT score: 2 (non-problematic) at 6 months
• ✓GAD-7 score: 4 (minimal anxiety) at 3 months
• ✓Liver enzymes normalized by month 4 (ALT 22, AST 19)
• ✓Panic attacks resolved completely
• ✓Re-engaged with social life, joined support community

Measurable Results by Condition

What Changes After Ibogaine Treatment

From Assessment to Sustained Recovery

Why Ibogaine Produces Measurable Before/After Differences

Unlike conventional treatments that manage symptoms indefinitely, ibogaine works through a single-session neurological reset. It simultaneously addresses physical withdrawal (opioid receptor modulation), psychological trauma (default mode network disruption), and neuroplasticity (GDNF/BDNF upregulation), producing rapid, measurable changes that are sustained by the long-acting metabolite noribogaine.

• Opioid receptor reset: eliminates physical withdrawal in 24-48 hours
• Default mode network disruption: allows trauma reprocessing similar to years of therapy
• GDNF/BDNF upregulation: promotes neuroplasticity for 8-12 weeks post-treatment
• Noribogaine metabolite: 28-49 hour half-life provides sustained stabilization
• Multi-receptor action: simultaneously addresses addiction, mood, and cognition
• Neuroplasticity window: 90 days of enhanced capacity for behavioral and neural rewiring

How We Track Before & After Outcomes

Every MindScape patient undergoes validated clinical assessments before treatment, at 24 hours, 7 days, 30 days, and 90 days post-treatment. For addiction: COWS (Clinical Opiate Withdrawal Scale), AUDIT (alcohol), DAST (drugs). For mental health: CAPS-5 (PTSD), PHQ-9 (depression), GAD-7 (anxiety). For cognition: MoCA (cognitive function).

Our clinical database tracks over 40 biomarkers and patient-reported outcomes. This systematic approach allows us to provide evidence-based outcome data rather than anecdotal testimonials. We publish aggregated outcomes while maintaining individual patient confidentiality.

We also conduct long-term follow-up at 6 and 12 months via telehealth check-ins with our integration team. This longitudinal tracking enables us to identify factors that predict the strongest sustained outcomes — the most important being engagement with our 90-day aftercare program.

Common Questions